Kiniksa carries a fortress-like capital structure with only $7.9M total debt, a 3.91 current ratio, and $710.2M equity, though liabilities have compounded 154% versus an 81% rise in assets since 2024Q2.
Kiniksa Pharmaceuticals International, plc (KNSA) balance sheet — 10-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 |
|---|
| Total Current Assets | 750.1M | 527.18M | 331.8M | 276.3M | 243.06M | 196.45M | 333.25M | 241.63M | 313.75M | 47.1M | 56.33M |
| Cash & Short-Term Investments | 568.76M | 414.07M | 243.63M | 206.37M | 190.61M | 182.2M | 323.48M | 233.38M | 307.3M | 45.55M | 55.97M |
| Cash Only | 81.66M | 165.6M | 183.58M | 107.95M | 122.72M | 122.47M | 114.04M | 46.93M | 307.3M | 45.55M | 55.97M |
| Short-Term Investments | 487.1M | 248.48M | 60.05M | 98.42M | 67.89M | 59.73M | 209.44M | 186.45M | 0 | 0 | 0 |
| Accounts Receivable | 30.78M | 15.59M | 41.72M | 21.27M | 20.32M | 3.98M | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | 8.98 | 8.4 | 35.98 | 28.72 | 33.68 | 37.74 | - | - | - | - | - |
| Inventory | 108.03M | 54.9M | 26.36M | 31.12M | 21.6M | 3.67M | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 64.74 | 65.18 | 157.98 | 200.97 | 344.34 | 147.4 | - | - | - | - | - |
| Other Current Assets | 42.53M | 42.61M | 20.08M | 17.54M | 10.54M | 0 | 210K | 0 | 6.45M | 105K | 105K |
| Total Non-Current Assets | 233.14M | 236.46M | 248.75M | 250.03M | 216.61M | 36.35M | 16.21M | 12.91M | 8.21M | 388K | 133K |
| Property, Plant & Equipment | 9.85M | 11.75M | 11.04M | 12.66M | 7.04M | 8.38M | 10.62M | 8.32M | 6.36M | 125K | 84K |
| Fixed Asset Turnover | 86.29x | 57.67x | 38.34x | 21.34x | 31.26x | 4.60x | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 14.5M | 15.25M | 16.25M | 17.25M | 18.25M | 19.25M | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 210K | 0 | 0 |
| Other Non-Current Assets | 10.75M | 11.31M | 10.31M | 827K | 5.82M | 8.72M | 5.59M | 210K | 643K | 25K | 8K |
| Total Assets | 983.24M | 763.63M | 580.55M | 526.32M | 459.67M | 232.8M | 349.46M | 254.53M | 321.96M | 47.49M | 56.47M |
| Asset Turnover | 1.09x | 0.89x | 0.73x | 0.51x | 0.48x | 0.17x | - | - | - | - | - |
| Asset Growth % | 142.81% | 31.54% | 10.3% | 14.5% | 97.45% | -33.38% | 37.3% | -20.94% | 577.94% | -15.89% | - |
| Total Current Liabilities | 191.85M | 139.18M | 100.62M | 63.67M | 47.07M | 44.82M | 31.85M | 27.83M | 42.55M | 17.43M | 2.3M |
| Accounts Payable | 4.11M | 2.03M | 2.04M | 8.25M | 7.9M | 1.87M | 503K | 5.69M | 10.92M | 1.22M | 212K |
| Days Payables Outstanding | 9.06 | 2.41 | 12.22 | 53.25 | 125.93 | 74.93 | 48.25 | 633.71 | 13.93K | 15.88K | 3.52K |
| Short-Term Debt | 0 | 2.99M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 63.62M | 31.81M | 0 | 307K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 20.26M | 102.36M | 33.12M | 36.91M | 16.97M | 1.54M | 7.74M | 7.11M | 25.96M | 14.64M | 1.1M |
| Current Ratio | 3.91x | 3.79x | 3.30x | 4.34x | 5.16x | 4.38x | 10.46x | 8.68x | 7.37x | 2.70x | 24.47x |
| Quick Ratio | 3.35x | 3.39x | 3.04x | 3.85x | 4.71x | 4.30x | 10.46x | 8.68x | 7.37x | 2.70x | 24.47x |
| Cash Conversion Cycle | 64.66 | 71.17 | 181.75 | 176.44 | 252.09 | 110.22 | - | - | - | - | - |
| Total Non-Current Liabilities | 81.19M | 56.84M | 41.5M | 23.82M | 16.46M | 2.94M | 5.68M | 1.28M | 144K | 119.77M | 79.9M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 21.16M | 6.51M | 7.86M | 10.01M | 2.62M | 2.67M | 4.88M | 955K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.22M | 0 | 0 |
| Other Non-Current Liabilities | 45.47M | 18.52M | 1.82M | 1.86M | 1.84M | 270K | 805K | 326K | 144K | 119.77M | 79.9M |
| Total Liabilities | 273.05M | 196.03M | 142.12M | 87.48M | 63.52M | 47.76M | 37.53M | 29.11M | 42.7M | 137.2M | 82.2M |
| Total Debt | 7.88M | 9.5M | 9.86M | 12.26M | 5.92M | 6.05M | 6.99M | 2.65M | 0 | 0 | 0 |
| Net Debt | -73.78M | -156.1M | -173.73M | -95.7M | -116.8M | -116.42M | -107.05M | -44.28M | -307.3M | -45.55M | -55.97M |
| Debt / Equity | 0.01x | 0.02x | 0.02x | 0.03x | 0.01x | 0.03x | 0.02x | 0.01x | - | - | - |
| Debt / EBITDA | 0.06x | 0.12x | - | - | 0.49x | - | - | - | - | - | - |
| Net Debt / EBITDA | -0.56x | -1.98x | - | - | -9.59x | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 710.19M | 567.61M | 438.44M | 438.84M | 396.15M | 185.04M | 311.94M | 225.42M | -194.22M | -89.71M | -25.73M |
| Equity Growth % | 126.66% | 29.46% | -0.09% | 10.78% | 114.09% | -40.68% | 38.38% | 216.06% | -116.51% | -248.62% | - |
| Book Value per Share | 8.36 | 7.19 | 6.14 | 6.10 | 5.63 | 2.70 | 5.04 | 4.17 | -6.57 | -2.76 | -0.79 |
| Total Shareholders' Equity | 710.19M | 567.61M | 438.44M | 438.84M | 396.15M | 185.04M | 311.94M | 225.42M | -194.22M | -89.71M | -25.73M |
| Common Stock | 21K | 21K | 20K | 20K | 19K | 18K | 18K | 15K | 13K | 1K | 1K |
| Retained Earnings | -366.77M | -462.14M | -521.14M | -477.95M | -492.03M | -675.4M | -517.47M | -356.09M | -194.22M | -91M | -26.13M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2.75M | -25K | -163K | 6K | 44K | -66K | -34K | 33K | -4K | -52K | -24K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying KNSA stock.
As of 2025, Kiniksa Pharmaceuticals International, plc (KNSA) had total assets of $763.6M including $527.2M in current assets.
Kiniksa Pharmaceuticals International, plc (KNSA) carries total debt of $9.5M, offset by $414.1M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Kiniksa Pharmaceuticals International, plc (KNSA) has total shareholders' equity (book value) of $567.6M ($7.19 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Kiniksa Pharmaceuticals International, plc (KNSA) reported a current ratio of 3.79x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Partner profit-share obligations outpacing cash
Metrics are mathematically derived from official filings.
Self-Funded Balance Sheet Compounding
Over ten quarters, Kiniksa's total equity expanded from $435.1M to $710.2M while accumulated retained losses narrowed by roughly $133M, based on the company's quarterly balance sheets, indicating the commercial ramp is now self-funding asset growth without external capital.
Total assets nearly doubled from $542.4M to $983.2M while total debt simultaneously declined from $11.4M to $7.9M, a combination that suggests the ARCALYST ramp is absorbing growth requirements organically rather than through leverage. The fact that the D/E ratio compressed from 0.03 to 0.01 during this expansion implies improving balance sheet quality concurrent with, not in place of, the operating leverage flagged in the income statement. Investors should treat this trajectory as consistent with a business moving from capital-dependent to self-sustaining, though the pace depends on ARCALYST volume continuation.
Asset-Light Model Concentrated in Working Capital
Goodwill of $14.5M and net PPE of just $9.9M together comprise under 3% of Kiniksa's $983.2M asset base, according to the reported balance sheet, confirming an asset-light commercial model where value sits in working capital rather than fixed capital.
Net PPE drifted lower from $12.4M to $9.9M over the period even as revenue expanded roughly 160%, implying the company is essentially running off its installed base with minimal reinvestment, which aligns with the sub-0.4% capex intensity observed in cash flow statements. This profile supports high cash conversion but leaves little cushion if manufacturing or scale-up investment is later required. The steady sequential decline in goodwill from $16.8M to $14.5M warrants further investigation as either impairment or revaluation, though either interpretation would be immaterial at under 1.5% of total assets.
Equity Growth Partly Non-Cash in Nature
Equity's $275M expansion since 2024Q2 appears only partly earnings-driven, as accumulated retained losses still stand at -$366.8M, and per Kiniksa's filings stock-based compensation reached $13.1M in 2026Q3, suggesting a meaningful share of book value growth stems from non-cash issuance.
Retained losses narrowed materially from -$521.1M at 2024Q4 to -$366.8M at 2026Q3, confirming genuine earned-capital accumulation since the 2025Q1 profitability inflection rather than a balance sheet propped up by capital raises. However, the residual gap between the $275M equity build and the $154M of retained-loss recovery implies common stock and APIC additions are doing real work, and with SBC rising from $3.9M to $13.1M quarterly, investors should monitor whether issuance is diluting per-share claims on the growing asset base. The absence of meaningful buybacks means this dilution is not being offset on the repurchase line.
Ample Buffer Despite Cash Drawdown
Kiniksa's current ratio held at 3.91 in 2026Q3 even as cash fell to $81.7M from $190.0M two quarters earlier, according to reported balance sheets, yet with only $7.9M of total debt the near-term obligation burden remains negligible.
The cash decline of roughly $108M from the 2026Q1 peak occurred alongside rising liabilities, so the composition of that outflow—whether partner profit-share settlements, operating investment, or working capital timing—warrants scrutiny even though free cash flow was positive in the same period. Importantly, the current ratio has actually improved from 3.24 to 3.91 across the ten quarters, indicating current assets are growing faster than current liabilities and the liquidity cushion is not eroding on a relative basis. With D/E at 0.01 and no refinancing wall evident, the company's shock absorption appears to come from working capital flexibility rather than cash stock alone.
Deferred Revenue Signals Partner Dependency
Deferred revenue of $31.8M in 2026Q3, down sharply from $63.6M in the prior quarter but still nearly triple the $11.8M carried in 2024Q2, as disclosed in Kiniksa's balance sheets, signals collaboration-related obligations that may flatter near-term revenue visibility.
The alternating $31.8M and $63.6M pattern across recent quarters suggests deferred balances are driven by episodic collaboration milestones rather than a steady stream of prepayments from ARCALYST demand, which would make this a lumpy rather than reliable leading indicator. The tripling of the balance versus 2024 does indicate expanding partner commitments, but the quarter-to-quarter volatility means investors should not read sequential changes as a directional demand signal. Because this sits on the liability side, its eventual recognition will inflate reported revenue without corresponding incremental cash, a nuance relevant when reconciling the top-line acceleration noted in the income statement review.
Liabilities Compounding Faster Than Assets
Total liabilities grew 154% to $273.1M since 2024Q2 versus an 81% rise in assets, while cash slipped to $81.7M, as shown in Kiniksa's quarterly reports, suggesting obligations are compounding faster than the liquid buffer despite a comfortable 3.91 current ratio.
Because debt is nearly absent at $7.9M, the liability build is necessarily operating in character—plausibly accrued profit-share obligations to Regeneron, payables, and collaboration deferrals—meaning headline leverage metrics of 0.01 D/E understate the true claims ranking ahead of shareholders. The current ratio masks this because current assets have been inflated by the same working-capital dynamics driving payables growth, so the quality of that 3.91 figure depends on receivable collectability and inventory posture rather than cash alone. Given cash now sits 18% below its 2024Q2 level while obligations have more than doubled, the interplay between partner settlements and the cash position is the balance sheet item most likely to surprise investors if ARCALYST growth decelerates.